Celldex Therapeutics, Inc. (CLDX) analyst actions
Rating and price-target actions on CLDX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CLDX overview →
3 measured CLDX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism | Press release | -0.64% | -5.45% | |
| Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis | Press release | +0.81% | +2.30% | |
| Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria | Press release | -0.37% | -0.30% |
Keep exploring
More CLDX: earnings → · SEC filings → · CLDX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | 257 | -0.63% | 42% |
| Addus HomeCare Corporation (ADUS) | 256 | -0.02% | 47% |
| Prothena Corporation plc - Ordinary Shares (PRTA) | 256 | -0.04% | 49% |
| Xeris Biopharma Holdings, Inc. (XERS) | 256 | +0.32% | 57% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.